Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

Fig. 6

The oncogenesis of CML cells was impaired by Ab@Tf-Cou6-PLGA NPs in vivo. a Treatment schedule for CML mice model. b The maximum WBC counts of mice were recorded. c, d The weights of the liver and spleen of mice were measured. e The percent of CD45+ cells in the bone marrow of mice were detected by FCM. f Cells from bone marrow, liver, and spleen of mice were tested by Wright’s stain. The arrows indicate leukemic cells. Scale bar, 10 μm. g The expression of BCR/ABL was observed by immunofluorescence test. Scale bar, 10 μm. h The survival curves of mice were analyzed by Kaplan–Meier methods. Data are presented as the means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page